Book a Meeting

Non-Fucosylated Anti-Human Amyloid beta (BAN2401) Therapeutic Antibody (CAT#: BioBet-579ZP) Datasheet

Target
Amyloid beta
Isotype
IgG1
Description
ADCC-Enhanced anti-Amyloid beta (BAN2401) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Alzheimer's Disease
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Amyloid beta antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
APP
Full Name
amyloid beta (A4) precursor protein
Background
This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. In addition, two of the peptides are antimicrobial peptides, having been shown to have bacteriocidal and antifungal activities. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.
Alternative Names
APP; Amyloid Beta; amyloid beta (A4) precursor protein
Gene ID
UniProt ID
Cellular Localization
Plasma membrane, Extracellular region or secreted, Nucleus, Endosome
Involvement in Disease
Diseases associated with APP include Cerebral Amyloid Angiopathy, App-Related and Alzheimer Disease.
Related Pathways
Its related pathways are Neuroscience and Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways.
Function
As a cell surface receptor, it performs physiological functions related to neurite growth, neuron adhesion, and axon formation on the surface of neurons. Interactions between APP molecules on adjacent cells promote synapse formation. Participate in cell migration and transcription regulation through protein interactions. Combined with G(O) and JIP-mediated apoptosis induction pathway. Inhibition of G(o)-atp enzyme activity (through similarity). As a kind of kinin I membrane receptor, it mediates the axonal transport of secretase and early protein 1 (similar). By acting as a kinesin I membrane receptor, it plays a role in the anterograde transport of axons to synapes. Participate in copper homeostasis/oxidative stress through the reduction of copper ions.
Field of research
Cell Biology and Cellular Response antibody; Cell Death antibody; Developmental Biology antibody; Neuroscience antibody; Signaling Transduction antibody
Post-translational modifications
Phosphorylation at Ser-410 by PKA severely impairs binding to OCRL.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BAN2401
Host
Humanized
Species Reactivity
Human
Description
BAN2401 is a humanized IgG1 monoclonal antibody (mAb) that selectively binds to large soluble beta-amyloid protofibrils and is thought to enhance their clearance and/or neutralize their neurotoxicity. Soluble beta-amyloid oligomers and large protofibrils have been implicated in mediating neurotoxicity in Alzheimer's disease (AD).
Indication
Alzheimer's Disease

Alzheimer's Disease

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany